Some of the FDA approved mAb for targeted drug delivery in cancer cells include; Rituximab for the treatment of B-cell non-Hodgkin’s lymphoma, Trastuzumab for the treatment of human epidermal growth factor receptor 2 (HER2) expressing breast cancer, Bevacizumab for the treatment of vascular VEGFR expressing colorectal cancer, Cetuximab for the treatment of EGFR expressing colorectal cancer and head/neck cancer [4,43,44,45,46]. Here, ERBB2 is linked to colorectal cancer.